<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31334681</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7-8</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>ALS/SURV: a modification of the CAFS statistic.</ArticleTitle><Pagination><StartPage>576</StartPage><EndPage>583</EndPage><MedlinePgn>576-583</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2019.1643375</ELocationID><Abstract><AbstractText>We present a composite endpoint that can be used in amyotrophic lateral sclerosis (ALS) trials, which combines functional status (via the ALS functional rating scale) and survival, denoted ALS/SURV. ALS/SURV modifies and extends the combined assessment of function and survival (CAFS) score and assigns rankings to participants that withdraw or are lost to follow up in a way that does not disproportionately lower and skew ranks for those participants that reach study endpoint (either death or study completion). ALS/SURV has properties of: (1) ordering participants that completed the study from the shortest surviving participant to the last observed death followed by worst function to best function; (2) ordering participants withdrawing at time of withdrawal by their decline in functional status relative to all the participants still in the study; and (3) then maintaining this ordering at time of withdrawal relative to participants still in the study. These properties allow ALS/SURV to better account for participant drop out compared to CAFS. We derive and compare the rankings of participants from the ceftriaxone treatment trial for ALS/SURV and CAFS and demonstrate that ALS/SURV does not modify the ordering of participants that complete a study by the results of participants who withdraw. Additionally, ALS/SURV can be summarized as either median functional status or median survival along with interquartile range, thereby adding clinical meaning to the statistic. Finally, by applying normal deviates, confidence intervals can be computed and used to estimate power for future studies. In summary, the above properties support the role for ALS/SURV as a new ALS composite statistic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan , Ann Arbor , MI , USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program for Neurology Research and Discovery, University of Michigan , Ann Arbor , MI , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Morton B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan , Ann Arbor , MI , USA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan , Ann Arbor , MI , USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program for Neurology Research and Discovery, University of Michigan , Ann Arbor , MI , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="Y">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31334681</ArticleId><ArticleId IdType="mid">NIHMS1536603</ArticleId><ArticleId IdType="pmc">PMC6768708</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1643375</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Journal of the neurological sciences 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ensor H, Lee RJ, Sudlow C, Weir CJ. Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review. J Biopharm Stat 2016;26:859&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">26391022</ArticleId></ArticleIdList></Reference><Reference><Citation>Huque MF, Alosh M, Bhore R. Addressing multiplicity issues of a composite endpoint and its components in clinical trials. J Biopharm Stat 2011;21:610&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">21516560</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration 2013;14:162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2014;13:1083&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet Neurology 2013;12:1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Statistics in medicine 1999;18:1341&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399200</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Brown MB, Glass JD, et al. Long-term Phase &#xbd; intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol 2018;5:730&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearman C The Proof and Measurement of Association between Two Things. The American Journal of Psychology 1904;15:72&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">3322052</ArticleId></ArticleIdList></Reference><Reference><Citation>Plana-Ripoll O, Gomez G. Selecting the primary endpoint in a randomized clinical trial: The ARE method. J Biopharm Stat 2016;26:880&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">26400217</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch G, Beyersmann J. Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework. Statistics in medicine 2013;32:3595&#x2013;3608.</Citation><ArticleIdList><ArticleId IdType="pubmed">23553898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng CH, Wong WK. Analysis of a composite endpoint with longitudinal and time-to-event data. Statistics in medicine 2011;30:1018&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">21341299</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Zhang H, Boss J, et al. Complete hazard ranking to analyze right-censored data: An ALS survival study. PLoS Comput Biol 2017;13:e1005887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5749893</ArticleId><ArticleId IdType="pubmed">29253881</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M, Gao C, Goutman SA, et al. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering. Neuroinformatics 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527505</ArticleId><ArticleId IdType="pubmed">30460455</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of neurology 2015;262:1447&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469087</ArticleId><ArticleId IdType="pubmed">25860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl SR, Kim RB, Coan GS, Mitchell CS. Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction. Front Neuroinform 2018;12:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010549</ArticleId><ArticleId IdType="pubmed">29962944</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, Eijkemans MJ, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clinical epidemiology 2018;10:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>